Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  NOTES TO ACCOUNT
Notes Of Account      
 
Year End: March 2016

Disclosure of accounting policies, change in accounting policies and changes in estimates explanatory

1. Corporate Information

Gland Pharma Limited (‘the Company) is a public limited Company domiciled in India and is primarily engaged in manufacturing injectable formulations. The Company has brsently three divisions namely Bulk Drugs (one unit is in SEZ), Formulations and Research &Development.

2. Basis of brparation

The financial statements of the Company have been brpared in accordance with Generally Accepted Accounting Principles in India (Indian GAAP). The Company has brpared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014. The financial statements have been brpared as a going concern on an accrual basis and under the historical cost convention. The accounting policies adopted in the brparation of financial statements are consistent with those of the brvious year.

2.1 Statement of significant accounting policies

(a) Use of estimates

The brparation of financial statements in conformity with Indian GAAP requires the Management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting year. Although these estimates are based on the Managements best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring materialadjustments to the carrying amounts of assets or liabilities in future years.

(b) Tangible fixed assets

Tangible Fixed assets are stated at cost, net of accumulated debrciation. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its brviously assessed standard of performance or extends its estimated useful life. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the year during which such expenses are incurred.

Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

(c) Debrciation on tangible fixed assets

Debrciation on fixed assets is calculated on a straight-line basis using the rates arrived at based on the useful lives estimated by the management. The management has estimated, supported by independent assessment by professionals, the useful lives of the following classes of assets.

Asset

Useful lives estimated by the management (years)

Factory buildings

30

Tube wells

5

Plant and Equipment

10-20

Laboratory Equipment

10

Office Equipment

5

Furniture and fixtures

5-10

Vehicles

8-10

Computers

3-6

(d) Government grants and subsidies

Grants and subsidies are recognized when there is a reasonable assurance that the grant or subsidy will be received and that all underlying conditions thereto will be complied with. Government grants of the nature of promoters contribution are credited to capital reserve and treated as a part of the shareholders funds.

(e) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognised as an expense in the statement of Profit and Loss.

(f) Impairment

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the assets recoverable amount. An assets recoverable amount is the higher of an assets or cash-generating units (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their brsent value using a br-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used.

(g) Investments

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.

(h) Inventories

Raw materials,packing materials, stores, spares and consumablesare valued at lower of cost and net realizable value. However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost of raw materials, packing material,stores, spares and consumables is determined on first in first out basis.

Work-in-progress and finished goods are valued at lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

(i) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Sale of goods

Revenue from sale of goods is recognised on dispatch which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, sales returns and sales tax, where applicable, and the additional amount in case of exclusive arrangement, is recognised based on the terms of the agreement entered into with the customers,in the period when the collectability of the profit share becomes probable and a reliable measure of the profit share is available. Excise duty deducted from revenue (gross) is the amount that is included in revenue (gross) and not the entire amount of liability arising during the year.

Sale of Services

Revenue from sale of dossiers/licenses/services is recognized in accordance with the terms of the relevant agreements as accepted and agreed with the customers.

Royalty Income:

Royalty income is recognized in accordance with the terms of the relevant agreements as accepted and agreed with the customers.

Interest income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head other income in the statement of profit and loss.

(j) Export benefits, incentives and licenses

Export benefits on account of duty drawback and export promotion schemes are accrued and accounted in the year of export, and are included in other operating revenue.

(k) Foreign currency translation

i) Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ii) Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

iii) Exchange differences

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in brvious financial statements, are recognised as income or as expenses in the year in which they arise.

(l) Retirement and other employee benefits

Retirement benefit in the form of provident fund is a defined contribution scheme and the contributions are charged to the statement of profit and loss for the year when the contributions to the fund are due. The Company has no obligation, other than the contributions payable to the provident fund authorities.

Gratuity liability is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to statement of profit and loss and are not deferred.

The Company treats accumulated leave, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company brsents the entire liability in respect of leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

(m) Income taxes

Tax expense comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.

Deferred income taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years. Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. In situations where the Company has unabsorbed debrciation or carry forward tax losses, the entire deferred tax assets are recognised only if there is virtual certainty supported by convincing evidence that such deferred tax assets can be realised against future taxable profits.

In the situations where the company is entitled to a tax holiday under the Income-tax Act, 1961 enacted in India or tax laws brvailing in the respective tax jurisdictions where it operates, no deferred tax (asset or liability) is recognized in respect of timing differences which reverse during the tax holiday period, to the extent the companys gross total income is subject to the deduction during the tax holiday period. Deferred tax in respect of timing differences which reverse after the tax holiday period is recognized in the year in which the timing differences originate. However, the company restricts recognition of deferred tax assets to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized. For recognition of deferred taxes, the timing differences which originate first are considered to reverse first.

(n) Segment reporting policies

Identification of segments

The Companys operating businesses are organized and managed separately according to the nature of products and services provided, with each segment rebrsenting a strategic business unit that offers different products and serves different markets. The analysis of geographical segments is based on the areas in which major operating divisions of the Company operate.

Inter-segment transfers

The Company generally accounts for intersegment sales and transfers at cost plus appropriate margins.

Allocation of common costs

Common allocable costs are allocated to each segment according to the relative contribution of each segment to the total common costs.

Unallocated items

The unallocated items include general corporate income and expense items which are not allocable to any business segment.

Segment accounting policies

The Company brpares its segment information in conformity with the accounting policies adopted for brparing and brsenting the financial statements of the Company as a whole.

(o) Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(p) Provisions

A provision is recognised when the Company has a brsent obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their brsent value and are determined based on the best estimate of the amount required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is brsented in the statement of profit and loss net of any reimbursement.

(q) Contingent liabilities

A contingent liability is a possible obligation that may arise as a result of past events whose existence may be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond control of the Company or a brsent obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognised because it cannot be measured reliably. The Company does not recognise a contingent liability but discloses its existence in the financial statements.

(r) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

(s) Research and development

Revenue expenditure on research and development is charged to revenue in the year in which it is incurred. Capital expenditure on research and development is added to fixed assets and debrciated in accordance with the policies of the Company.

25.Earnings per share

The following reflects the profit and share data used in the basic and diluted EPS computations:

March 31, 2016

March 31, 2015

Net profit for calculation of EPS

3,136,063,354

2,092,666,385

Weighted average no. of equity shares in calculating Basic EPS

15,567,695

14,085,021

Weighted average no. of equity shares in calculating Diluted EPS

15,567,695

14,803,419

Basic Earnings per share

201.45

148.57

Diluted Earnings per share

201.45

141.36

26.Retirement benefits:

Disclosures related to defined contribution plan

Provident fund contribution recognized as expense in Statement of Profit and Loss is Rs. 50,987,746 (March 31, 2015: 41,827,937)

Defined Benefit Plans

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service is entitled to a gratuity on departure at 15 days salary for each completed year of service. The Scheme is funded. The following tables summarise net benefit expense/incomerecognised in the statement of profit and loss, the status of funding and the amount recognised in the Balance sheet for the gratuity plan:

Statement of profit and loss

Net employee benefit expenses recognized in the employee cost

March 31, 2016

March 31, 2015

Current service cost

5,566,342

4,608,005

Interest cost on benefit obligation

5,792,672

5,209,846

Expected return on plan assets

(6,588,857)

(5,216,739)

Net actuarial loss/(gain) recognized in the year

7,865,697

333,798

Premium expense

232,316

-

Net benefit expense/ (income)

12,868,170

4,934,910

Actual return on plan assets

6,588,857

5,216,739

Amount recognized in the balance sheet

March 31, 2016

March 31, 2015

Defined benefit obligation

86,956,725

72,408,402

Fair value of plan assets

(95,142,050)

(74,267,566)

Net (Asset)/ Liability

(8,185,325)

(1,859,164)

Changes in the brsent value of the defined benefit obligation:

March 31, 2016

March 31, 2015

Opening defined benefit obligation

72,408,402

65,123,073

Current service cost

5,566,342

4,608,005

Interest cost

5,792,672

5,209,846

Benefits paid

(4,676,388)

(2,866,320)

Actuarial losses/(gains) on obligation

7,865,697

333,798

Closing defined benefit obligation

86,956,725

72,408,402

Changes in the fair value of plan assets are as follows:

March 31, 2016

March 31, 2015

Opening fair value of plan assets

74,267,566

55,810,551

Expected return on plan assets

6,588,857

5,216,739

Contributions

19,194,331

16,106,596

Benefits paid

(4,676,388)

(2,866,320)

Premium expense

(232,316)

-

Closing fair value of plan assets

95,142,050

74,267,566

The Company expects to contribute Rs. 19,000,000 to gratuity in the year 2016-17 as per the actuarial valuation.

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

March 31, 2016

March 31, 2015

Investment with the insurer

100%

100%

The overall expected rate of return on assets is determined based on the actual rate of return during the current year.

The principal assumptions used in determining gratuity obligations for the Companys plans are shown below:

March 31, 2016

March 31, 2015

Discount rate

8.00%

8.00%

Expected rate of return on assets

8.35%

9.00%

Salary rise

8.00%

8.00%

Attrition rate

10.00%

10.00%

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

27.Segment reporting

Business segment:

Segments are identified in line with AS 17 'Segment Reporting', taking into consideration the internal organisation and management structure as well as the differential risk and returns of the segment.

Based on the Companys business model of vertical integration, pharmaceuticals have been considered as the only reportable business segment and hence no separate financial disclosures provided in respect of its single business segment.

Geographical segments:

Although the Companys operating divisions are managed on a worldwide basis, they operate in five major geographical areas of the world, in India (its home country), North America, Europe, South America and Rest of World.

Information in respect of Geographical Segment:

For the financial year ended March 31, 2016

Segment revenue

Carrying amount of segment assets

India

3,315,225,404

17,790,559,566

North America

7,492,656,687

1,869,582,771

South America

1,824,608,411

873,643,628

Europe

430,324,747

139,419,569

Rest of the world

512,157,821

189,899,449

Total

13,574,973,070

20,863,104,983

­

For the financial year ended March 31, 2015

Segment revenue

Carrying amount of segment assets

India

2,395,070,029

16,304,505,146

North America

5,369,237,006

892,214,235

South America

997,311,005

122,218,976

Europe

719,984,038

115,917,256

Rest of the world

534,367,398

146,512,107

Total

10,015,969,476

17,581,367,720

The Company has entire fixed assets situated within India for producing goods to sell in domestic as well as overseas markets. Hence, separate figures for fixed assets/ additions to fixed assets have not been furnished.

28.Related party disclosures

Names of related parties and related party relationship

i. Related parties where control exists:

Description of relationship

Name of the related party

Enterprises in which directors are interested as directors, where transactions exists

Gland Chemicals Private Limited

Nicomac Clean Rooms Fast East Private Limited

Moreschi Asia Doors Private Limited

WockhardtLimited

Limited Liability Firms in which directors are interested as partner, where transaction exists

DhananjayaProperties LLP

SasikalaProperties LLP

Key management personnel

Sri P.V.N. Raju, Chairman and Director

Dr.RaviPenmetsa, Vice Chairman and Managing Director

Srinivas Sadu, Chief Operating Officer and Whole Time Director

B.Narasimha Rao, Chief Financial Officer and Whole Time Director

Mrs K Jhansi Lakshmi, Vice President (Finance) and Whole Time Director (w.e.f August 04, 2015)

Relatives of the Director

Mrs K Jhansi Lakshmi, Vice President (Finance)

Smt. P. Suryakantham

K Praveen Kumar

NakulPenmetsa, Vice brsident (IBD)

ii. Related party transactions:

Name of party

Nature of transaction

For the year ended

March 31, 2016

For the year ended

March 31, 2015

Gland Chemicals Private Limited

Purchase of raw material

114,012,321

270,141,166

Nicomac Clean Rooms Far East Private Limited

Purchase of capital goods

114,997,720

113,955,760

Repairs and maintenance

-

672,508

Moreschi Asia Doors Private Limited

Purchase of capital goods

4,601,714

15,244,892

Repairs and maintenance

-

470,331

Wockhardt Limited

Sale of services

2,770,200

6,370,818

Sri P.V.N. Raju

Managerial Remuneration

5,272,041

5,424,636

Rent expense

172,617

156,924

Dr. Ravi Penmetsa

Managerial Remuneration including Commission

62,170,505

44,044,293

Rent expense

-

439,943

Mrs K Jhansi Lakshmi

Salary

1,995,200

5,028,000

Managerial Remuneration

3,990,400

-

Rent expense

1,553,299

1,497,199

B.Narasimha Rao

Managerial Remuneration

9,764,500

7,346,134

Srinivas Sadu

Managerial Remuneration

11,479,000

9,067,570

DhananjayaProperties LLP

Rent expense

1,920,000

960,000

SasikalaProperties LLP

Rent expense

1,182,206

411,126

SmtSasikalaPenmetsa

Rent expense

-

258,300

Smt. P. Suryakantham

Rent expense

172,617

156,924

K Praveen Kumar

Rent expense

116,481

-

NakulPenmetsa

Salary

1,202,085

-

Note: The remuneration to the key managerial personnel does not include the provisions made for gratuity and leave benefits, as they are determined on an actuarial basis for the company as a whole.

iii. Balances outstanding receivable/(payable):

Name of party

As at

March 31, 2016

As at

March 31, 2015

Dr. Ravi Penmetsa, Director

(45,565,430)

(26,961,899)

Gland Chemicals Private Limited

(20,780,790)

(33,148,992)

Nicomac Clean Rooms Far East Private Limited

(6,341,586)

45,008,754

Moreschi Asia Doors Private Limited

24,842

(2,856,455)

Wockhardt Limited

-

2,730,348

29.Contingent liability

March 31, 2016

March 31, 2015

a) Outstanding bank guarantees

24,588,293

15,335,041

b) Income tax case

855,890

3,274,080

c) Indirect tax cases against the Company

428,411,638

40,670,040

d) Claims against the Company not acknowledged as debts

13,141,559

17,333,222

e) The Company entered into a Secondary manufacturing agreement (agreement) dated April 19, 2002 with Genemedix PLC (Genemedix). As part of the agreement, Genemedix was required to install Lyophilzer in Companys factory and provide Company with raw material for performing secondary manufacturing. In 2002, Genemedix installed the asset, however, did not supply raw material for secondary manufacturing till 2008. In 2008, Genemedixclaimed for return of the Lyophilizer and USD 8,646,705 for commercial usage of Lyophilizer during last 6 years. The Company denied all the claims and filed a counter claim on July 14, 2008 claiming damages of USD 12,176,423 for loss of production during the installation and dismantling of machinery. The case is pending before the Sole Arbitrator Sri Justice B.P. Jeevan Reddy.

Based on internal assessment and / or advice from legal counsellors the management is confident that no provision is required to be made for the above contingent liabilities as at March 31, 2016.

30.Capital and other commitments

March 31, 2016

March 31, 2015

Estimated amount of contracts remaining to be executed on capital account and not provided for

795,348,072

1,902,261,049

31.Derivative instruments and unhedged foreign currency exposure

(a) The Company does not have any hedged derivatives as at March 31, 2016 and March 31, 2015.

(b) Un-hedged foreign currency exposures

March 31, 2016

March 31, 2015

Cash and bank balances

665,862,648

341,889,489

Trade receivables

3,046,542,861

1,274,717,383

Loans and advances

240,796,955

346,603,497

Trade payables

425,951,101

119,237,847

Other current liabilities

1,083,454,559

682,281,771

Foreign Currency Loans

399,000,000

377,040,000

32.Details of dues to micro and small enterprises as defined under the MSMED Act, 2006

March 31, 2016

March 31, 2015

The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year

Principal amount due to micro and small enterprises

41,805,245

10,294,688

Interest due on above

-

-

Total

41,805,245

10,294,688

33.CIF Value of Imports

March 31, 2016

March 31, 2015

Raw material, packing material, consumables and spare parts

4,446,382,320

3,068,013,514

Capital goods

1,109,004,062

691,852,848

Total

5,555,386,382

3,759,866,362

34.Research and development

March 31, 2016

March 31, 2015

Cost of material consumed

Raw material and packing material consumed

120,263,056

163,549,272

Other manufacturing expenses

Power and fuel

5,282,473

5,398,856

Repairs of plant and machinery

2,007,968

2,239,214

Chemicals and consumables

177,435,683

167,933,723

Employee benefit expenses

Staff cost

118,680,022

110,283,936

Other operating and selling expenses

Legal and professional charges

15,056,850

18,253,000

Printing and stationery

1,068,372

933,057

Other expenses

21,998,270

24,389,791

Travelling and conveyance

2,012,790

1,617,830

Repairs of computer and other assets

438,395

868,095

Total

464,243,878

495,466,774

35.Expenditure in foreign currency (on accrual basis)

March 31, 2016

March 31, 2015

Rates, taxes and licenses

89,961,253

106,115,432

Legal and professional charges

7,529,185

8,148,963

Sales commission

-

8,342,747

Interest expense

5,030,020

6,576,450

Research and development testing expenses

2,934,011

5,586,669

Business promotion expenses

3,599,741

1,974,740

Travelling expense

2,657,981

2,266,477

Bank charges

1,212,164

1,749,247

Rent expense

3,433,043

-

Others

4,400,586

1,786,052

Total

120,757,984

142,546,777

36. a) Imported and indigenous raw materials and packing material consumed

Particulars

% of total consumption March 31, 2016

Value (Rs.)

March 31, 2016

% of total consumption March 31, 2015

Value (Rs.) March 31,2015

Imported

75.56%

3,912,937,758

76.00%

2,996,820,285

Indigenous

24.44%

1,265,917,900

24.00%

946,261,507

Total

100.00%

5,178,855,658

100.00%

3,943,081,792

b) Imported and indigenous stores and spares consumed (included in various heads of other expenses)

Particulars

% of total consumption March 31, 2016

Value (Rs.)

March 31, 2016

% of total consumption March 31, 2015

Value (Rs.) March 31, 2015

Imported

20.24%

108,036,816

20.78%

82,718,166

Indigenous

79.76%

425,779,504

79.22%

315,373,070

Total

100.00%

533,816,320

100.00%

398,091,236

37.Earnings in foreign currency (on accrual basis)

March 31, 2016

March 31, 2015

Total earnings on account of exports

10,259,747,666

7,620,899,447

Total

10,259,747,666

7,620,899,447

38.Leases

Operating leases are mainly in the nature of lease of office brmises with no restrictions and are renewable/ cancellable at the option of either of the parties. The escalation rates range from 0% to 10% per annum as per the terms of the lease agreement. There are no sub-leases. There are no restrictions imposed by lease arrangements. The aggregate amount of operating lease payments recognized in the Statement of Profit and Loss is Rs. 56,163,629 (March 31, 2015: Rs. 38,463,205).

39.Prior period expense

Particulars

March 31, 2016

March 31, 2015

Legal and professional charges

-

6,931,821

Sales commission

-

4,441,360

Total

-

11,373,181

40. Corporate social responsibility

Particulars

March 31, 2016

March 31, 2015

Gross amount required to be spent during the year

54,257,026

44,987,370

Amount spent during the year

5,000,000

-

41.Figures of the brvious year have been regrouped / recast wherever necessary to compare with current years classification.As per our report of even date.

For S.R. Batliboi& Associates LLP

For and behalf of the Board of Directors of

ICAI Firm Registration No.: 101049W/E300004

Gland Pharma Limited

Chartered Accountants

per Vikas Kumar Pansari

Dr. Ravi Penmetsa

Srinivas Sadu

Partner

Vice Chairman and Managing Director

Whole Time Director and Chief Operating Officer

Membership No. 093649

B. Narasimha Rao

P. SampathKumar

Whole Time Director and Chief Financial Officer

Company Secretary

Place: Hyderabad

Place: Hyderabad

Place: Hyderabad

Date: June 24, 2016

Date: June 24, 2016

Date:June 24, 2016

Disclosure of general information about company

1. Corporate Information

Gland Pharma Limited (‘the Company) is a public limited Company domiciled in India and is primarily engaged in manufacturing injectable formulations. The Company has brsently three divisions namely Bulk Drugs (one unit is in SEZ), Formulations and Research &Development.

Disclosure of accounting policies explanatory

The financial statements of the Company have been brpared in accordance with Generally Accepted Accounting Principles in India (Indian GAAP). The Company has brpared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014. The financial statements have been brpared as a going concern on an accrual basis and under the historical cost convention. The accounting policies adopted in the brparation of financial statements are consistent with those of the brvious year.

Changes in accounting estimate and accounting policy explanatory

(a) Use of estimates

The brparation of financial statements in conformity with Indian GAAP requires the Management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting year. Although these estimates are based on the Managements best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring materialadjustments to the carrying amounts of assets or liabilities in future years.

Disclosure of enterprise's reportable segments explanatory

(a) Segment reporting policies

Identification of segments

The Companys operating businesses are organized and managed separately according to the nature of products and services provided, with each segment rebrsenting a strategic business unit that offers different products and serves different markets. The analysis of geographical segments is based on the areas in which major operating divisions of the Company operate.

Inter-segment transfers

The Company generally accounts for intersegment sales and transfers at cost plus appropriate margins.

Allocation of common costs

Common allocable costs are allocated to each segment according to the relative contribution of each segment to the total common costs.

Unallocated items

The unallocated items include general corporate income and expense items which are not allocable to any business segment.

Segment accounting policiesThe Company brpares its segment information in conformity with the accounting policies adopted for brparing and brsenting the financial statements of the Company as a whole

Disclosure of employee benefits explanatory

Retirement and other employee benefits

Retirement benefit in the form of provident fund is a defined contribution scheme and the contributions are charged to the statement of profit and loss for the year when the contributions to the fund are due. The Company has no obligation, other than the contributions payable to the provident fund authorities.

Gratuity liability is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to statement of profit and loss and are not deferred.

The Company treats accumulated leave, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company brsents the entire liability in respect of leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement for 12 months after the reporting date

Disclosures related to defined contribution plan

Provident fund contribution recognized as expense in Statement of Profit and Loss is Rs. 50,987,746 (March 31, 2015: 41,827,937)

Defined Benefit Plans

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service is entitled to a gratuity on departure at 15 days salary for each completed year of service. The Scheme is funded. The following tables summarise net benefit expense/incomerecognised in the statement of profit and loss, the status of funding and the amount recognised in the Balance sheet for the gratuity plan:

Statement of profit and loss

Net employee benefit expenses recognized in the employee cost

March 31, 2016

March 31, 2015

Current service cost

5,566,342

4,608,005

Interest cost on benefit obligation

5,792,672

5,209,846

Expected return on plan assets

(6,588,857)

(5,216,739)

Net actuarial loss/(gain) recognized in the year

7,865,697

333,798

Premium expense

232,316

-

Net benefit expense/ (income)

12,868,170

4,934,910

Actual return on plan assets

6,588,857

5,216,739

Amount recognized in the balance sheet

March 31, 2016

March 31, 2015

Defined benefit obligation

86,956,725

72,408,402

Fair value of plan assets

(95,142,050)

(74,267,566)

Net (Asset)/ Liability

(8,185,325)

(1,859,164)

Changes in the brsent value of the defined benefit obligation:

March 31, 2016

March 31, 2015

Opening defined benefit obligation

72,408,402

65,123,073

Current service cost

5,566,342

4,608,005

Interest cost

5,792,672

5,209,846

Benefits paid

(4,676,388)

(2,866,320)

Actuarial losses/(gains) on obligation

7,865,697

333,798

Closing defined benefit obligation

86,956,725

72,408,402

Changes in the fair value of plan assets are as follows:

March 31, 2016

March 31, 2015

Opening fair value of plan assets

74,267,566

55,810,551

Expected return on plan assets

6,588,857

5,216,739

Contributions

19,194,331

16,106,596

Benefits paid

(4,676,388)

(2,866,320)

Premium expense

(232,316)

-

Closing fair value of plan assets

95,142,050

74,267,566

The Company expects to contribute Rs. 19,000,000 to gratuity in the year 2016-17 as per the actuarial valuation.

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

March 31, 2016

March 31, 2015

Investment with the insurer

100%

100%

The overall expected rate of return on assets is determined based on the actual rate of return during the current year.

The principal assumptions used in determining gratuity obligations for the Companys plans are shown below:

March 31, 2016

March 31, 2015

Discount rate

8.00%

8.00%

Expected rate of return on assets

8.35%

9.00%

Salary rise

8.00%

8.00%

Attrition rate

10.00%

10.00%

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.